The country has the world’s largest number of multi-drug-resistant cases – but doctors and activists warn patients are going undiagnosed and untreated.

Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Senior TB Project Associate to support community engagement activities under the SMART4TB Project – a $200 million investment made by USAID to Support, Mobilize, and Accelerate Research for TB Elimination.

A massive analysis of more than 10,000 different Mycobacterium tuberculosis bacteria isolates from 23 countries has revealed new genes associated with resistance to 13 first- and second-line new and repurposed antibiotics. The work, carried out by Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (CRyPTIC), is described in two new papers publishing August 11^th in the open-access journal PLOS Biology.

Amidst longstanding debate on the effectiveness of the tuberculosis vaccine, a new study suggests that the vaccine is protective against TB in children under 5, but adolescents and adults in high-burden countries may need additional protection to maintain immunity beyond childhood.

Ukraine managed to sustain pre-war HIV and TB rates during its ongoing conflict with Russia due to mobile medical services and outreach. Andriy Klepikov, executive director of Alliance for Public Health, said Ukraine saw no outbreaks in HIV or TB over the past six months of conflict after Russia invaded the country last February 24.

“A key point when thinking about how to reduce AIDS-related mortality is to recognise that while scale-up of antiretroviral therapy (ART) is absolutely necessary for decreasing deaths, ART alone is not sufficient to achieve mortality reduction targets,” Dr Laura Broyles from the Global Health Impact Group told the International AIDS Conference (AIDS 2022) in Montreal, Canada, held on 29 July - 2 August 2022. The leading cause of mortality among people with advanced HIV disease are two treatable opportunistic infections: TB and cryptococcal meningitis.

4 August 2022: To address the global burden of tuberculosis (TB), one of humankind’s oldest scourges, an international collaboration led by Johns Hopkins Medicine has today been awarded up to $200 million in research funding over five years by the U.S. Agency for International Development (USAID) Supporting, Mobilizing and Accelerating Research for Tuberculosis Elimination (SMART4TB) project.

Led by Martina Kovarova, PhD, Miriam Braunstein, PhD, and J. Victor Garcia, PhD, UNC School of Medicine researchers showed in vivo efficacy of a long-acting injectable formulation of the anti-TB drug rifabutin.

The Stop TB Partnership released its July 2022 newsletter, presenting the initiatives and activities carried out during the month.

The immune boosting benefits of a tuberculosis vaccine can be seen in infants more than one year after vaccination, according to a new study.